Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

 Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

Shots:

  • Amgevita will be launched in 28 EU countries as well as Norway, Iceland and Liechtenstein making it 3rd EU Amgen’s approved biosimilar
  • EMA approved Amgevita in RA, PsA, AS, nr-axSpA, plague psoriasis, HS, non-infectious panuveitis, CD and UC in adults and CD, plague psoriasis, ERA and JIA in pediatric patients
  • Amgevita is an IgG1 mAb that deactivates TNFα and is available in a prefilled syringe & pen (SureClick autoinjector) for approved dosing in multiple indications

Click here to read full press release/ article | Ref: Amgen  | Image: Contract Pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post